FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2742450412> ?p ?o ?g. }

• W2742450412 endingPage "85525" @default.
• W2742450412 startingPage "85516" @default.
• W2742450412 abstract "// Kei Kawaguchi 1, 2, 3 , Kentaro Igarashi 1, 2 , Shukuan Li 1 , Qinghong Han 1 , Yuying Tan 1 , Tasuku Kiyuna 1, 2 , Kentaro Miyake 1 , 2 , Takashi Murakami 1, 2 , Bartosz Chmielowski 4 , Scott D. Nelson 5 , Tara A. Russell 6 , Sarah M. Dry 5 , Yunfeng Li 5 , Michiaki Unno 3 , Fritz C. Eilber 6 and Robert M. Hoffman 1, 2 1 AntiCancer, Inc., San Diego, CA, USA 2 Department of Surgery, University of California, San Diego, CA, USA 3 Department of Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan 4 Division of Hematology-Oncology, University of California, Los Angeles, CA, USA 5 Department of Pathology, University of California, Los Angeles, CA, USA 6 Division of Surgical Oncology, University of California, Los Angeles, CA, USA Correspondence to: Robert M. Hoffman, email: all@anticancer.com Fritz C. Eilber, email: fceilber@mednet.ucla.edu Keywords: recombinant methioninase, methionine dependence, metabolic targeting, temozolomide, melanoma Received: June 06, 2017     Accepted: July 06, 2017     Published: August 12, 2017 ABSTRACT An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant methioninase (rMETase). The present study used a previously-established patient-derived orthotopic xenograft (PDOX) nude mouse model of BRAF V600E-mutant melanoma to determine the efficacy of rMETase in combination with a first-line melanoma drug, temozolomide (TEM). In the present study 40 melanoma PDOX mouse models were randomized into four groups of 10 mice each: untreated control (n=10); TEM (25 mg/kg, oral 14 consecutive days, n=10); rMETase (100 units, intraperitoneal 14 consecutive days, n=10); combination TEM + rMETase (TEM: 25 mg/kg, oral rMETase: 100 units, intraperitoneal 14 consecutive days, n=10). All treatments inhibited tumor growth compared to untreated control (TEM: p =0.0081, rMETase: p =0.0037, TEM-rMETase: p =0.0024) on day 14 after initiation. However, the combination therapy of TEM and rMETase was significantly more efficacious than either mono-therapy (TEM: p =0.0051, rMETase: p =0.0051). The present study is the first demonstrating the efficacy of rMETase combination therapy in a PDOX model, suggesting potential clinical development, especially in recalcitrant cancers such as melanoma, where rMETase may enhance first-line therapy." @default.
• W2742450412 created "2017-08-17" @default.
• W2742450412 creator A5002607014 @default.
• W2742450412 creator A5005260055 @default.
• W2742450412 creator A5005261216 @default.
• W2742450412 creator A5017915063 @default.
• W2742450412 creator A5023556030 @default.
• W2742450412 creator A5039301683 @default.
• W2742450412 creator A5040819666 @default.
• W2742450412 creator A5047314223 @default.
• W2742450412 creator A5060520190 @default.
• W2742450412 creator A5070052371 @default.
• W2742450412 creator A5073758146 @default.
• W2742450412 creator A5077449490 @default.
• W2742450412 creator A5081080411 @default.
• W2742450412 creator A5084779266 @default.
• W2742450412 creator A5086139902 @default.
• W2742450412 date "2017-08-12" @default.
• W2742450412 modified "2023-09-29" @default.
• W2742450412 title "Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model" @default.
• W2742450412 cites W1239224350 @default.
• W2742450412 cites W1492549565 @default.
• W2742450412 cites W1530556189 @default.
• W2742450412 cites W1544424898 @default.
• W2742450412 cites W1569875761 @default.
• W2742450412 cites W1592125379 @default.
• W2742450412 cites W1805852575 @default.
• W2742450412 cites W1848282561 @default.
• W2742450412 cites W1896165692 @default.
• W2742450412 cites W1963404410 @default.
• W2742450412 cites W1965110439 @default.
• W2742450412 cites W1969705513 @default.
• W2742450412 cites W1978391889 @default.
• W2742450412 cites W1980325735 @default.
• W2742450412 cites W1992331783 @default.
• W2742450412 cites W1997855844 @default.
• W2742450412 cites W1998139955 @default.
• W2742450412 cites W1998296205 @default.
• W2742450412 cites W1999839653 @default.
• W2742450412 cites W2000710160 @default.
• W2742450412 cites W2009313952 @default.
• W2742450412 cites W2012110463 @default.
• W2742450412 cites W2014252256 @default.
• W2742450412 cites W2014844807 @default.
• W2742450412 cites W2015556936 @default.
• W2742450412 cites W2027818468 @default.
• W2742450412 cites W2028701135 @default.
• W2742450412 cites W2046367925 @default.
• W2742450412 cites W2052625497 @default.
• W2742450412 cites W2057881489 @default.
• W2742450412 cites W2059921126 @default.
• W2742450412 cites W2072823493 @default.
• W2742450412 cites W2081193330 @default.
• W2742450412 cites W2096870516 @default.
• W2742450412 cites W2107117572 @default.
• W2742450412 cites W2122134113 @default.
• W2742450412 cites W2128542677 @default.
• W2742450412 cites W2131746764 @default.
• W2742450412 cites W2132970134 @default.
• W2742450412 cites W2139283055 @default.
• W2742450412 cites W2159118239 @default.
• W2742450412 cites W2272577140 @default.
• W2742450412 cites W2278568674 @default.
• W2742450412 cites W2294356527 @default.
• W2742450412 cites W2306887830 @default.
• W2742450412 cites W2332572212 @default.
• W2742450412 cites W2342246138 @default.
• W2742450412 cites W2342714720 @default.
• W2742450412 cites W2347178913 @default.
• W2742450412 cites W2408339495 @default.
• W2742450412 cites W2418346118 @default.
• W2742450412 cites W2419037363 @default.
• W2742450412 cites W2444538184 @default.
• W2742450412 cites W249545773 @default.
• W2742450412 cites W2516251801 @default.
• W2742450412 cites W2527335053 @default.
• W2742450412 cites W2550476383 @default.
• W2742450412 cites W2568046113 @default.
• W2742450412 cites W2572657810 @default.
• W2742450412 cites W2593558254 @default.
• W2742450412 cites W2602989667 @default.
• W2742450412 cites W2605117891 @default.
• W2742450412 cites W279302623 @default.
• W2742450412 cites W347202097 @default.
• W2742450412 doi "https://doi.org/10.18632/oncotarget.20231" @default.
• W2742450412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5689627" @default.
• W2742450412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29156737" @default.
• W2742450412 hasPublicationYear "2017" @default.
• W2742450412 type Work @default.
• W2742450412 sameAs 2742450412 @default.
• W2742450412 citedByCount "60" @default.
• W2742450412 countsByYear W27424504122017 @default.
• W2742450412 countsByYear W27424504122018 @default.
• W2742450412 countsByYear W27424504122019 @default.
• W2742450412 countsByYear W27424504122020 @default.
• W2742450412 countsByYear W27424504122021 @default.
• W2742450412 countsByYear W27424504122022 @default.
• W2742450412 countsByYear W27424504122023 @default.

• next